Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,068 | 435 | 92.7% |
| Travel and Lodging | $309.08 | 1 | 4.7% |
| Education | $170.66 | 3 | 2.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,452 | 103 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,057 | 88 | $0 (2023) |
| Janssen Biotech, Inc. | $723.38 | 51 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $403.10 | 27 | $0 (2023) |
| Covidien LP | $322.96 | 2 | $0 (2017) |
| Ferring Pharmaceuticals Inc. | $262.32 | 19 | $0 (2023) |
| Ironwood Pharmaceuticals, Inc | $207.55 | 14 | $0 (2021) |
| Gilead Sciences, Inc. | $196.63 | 15 | $0 (2021) |
| Daiichi Sankyo Inc. | $185.87 | 13 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $182.15 | 10 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $276.96 | 19 | ABBVIE INC. ($134.99) |
| 2022 | $553.32 | 39 | ABBVIE INC. ($286.11) |
| 2021 | $1,100 | 74 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($249.42) |
| 2020 | $777.79 | 61 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($380.51) |
| 2019 | $863.77 | 64 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($227.16) |
| 2018 | $970.80 | 79 | AbbVie, Inc. ($180.46) |
| 2017 | $2,005 | 103 | AbbVie, Inc. ($556.28) |
All Payment Transactions
439 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/19/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: INTERNAL MEDICINE | ||||||
| 04/19/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: Gastroenterology | ||||||
| 03/30/2023 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: VIROLOGY | ||||||
| 03/23/2023 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: VIROLOGY | ||||||
| 03/21/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Iron Deficiency Anemia | ||||||
| 03/09/2023 | ABBVIE INC. | LINZESS (Drug), VIBERZI, CREON | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/08/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: INTERNAL MEDICINE | ||||||
| 03/08/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.89 | General |
| Category: Neuroscience | ||||||
| 03/05/2023 | ABBVIE INC. | RINVOQ (Biological), HUMIRA | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: IMMUNOLOGY | ||||||
| 03/02/2023 | ABBVIE INC. | RINVOQ (Biological), HUMIRA | Food and Beverage | In-kind items and services | $2.29 | General |
| Category: IMMUNOLOGY | ||||||
| 03/01/2023 | QOL Medical, LLC | Sucraid (Drug) | Food and Beverage | Cash or cash equivalent | $16.42 | General |
| Category: THERAPY FOR CSID | ||||||
| 03/01/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: IMMUNOLOGY | ||||||
| 02/22/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/08/2023 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/08/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: Gastroenterology | ||||||
| 02/08/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: IMMUNOLOGY | ||||||
| 01/26/2023 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $12.93 | General |
| Category: VIROLOGY | ||||||
| 01/19/2023 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/11/2023 | Ferring Pharmaceuticals Inc. | CIMZIA (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/30/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Gastroenterology | ||||||
| 11/30/2022 | ABBVIE INC. | LINZESS (Drug), VIBERZI, CREON | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/15/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.90 | General |
| Category: Neuroscience | ||||||
| 11/02/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $14.35 | General |
| Category: IMMUNOLOGY | ||||||
| 10/25/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: Immunology | ||||||
| 10/05/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 322 | 339 | $170,309 | $31,754 |
| 2022 | 16 | 987 | 14,650 | $1.2M | $338,438 |
| 2021 | 19 | 988 | 12,548 | $1.3M | $329,031 |
| 2020 | 21 | 1,020 | 6,919 | $621,933 | $200,285 |
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 96 | 97 | $19,400 | $5,970 | 30.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 22 | 22 | $28,695 | $4,956 | 17.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 54 | 54 | $15,336 | $4,642 | 30.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 21 | 21 | $22,470 | $3,970 | 17.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 39 | 39 | $38,800 | $3,029 | 7.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 16 | 16 | $20,720 | $2,031 | 9.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 21 | $6,111 | $1,998 | 32.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 17 | 21 | $9,387 | $1,881 | 20.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 27 | $4,224 | $1,794 | 42.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 21 | 21 | $5,166 | $1,483 | 28.7% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 20 | 13,500 | $688,500 | $227,452 | 33.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 244 | 330 | $66,000 | $23,481 | 35.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 174 | 205 | $58,220 | $19,988 | 34.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 65 | 65 | $69,092 | $12,497 | 18.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 121 | 121 | $130,160 | $8,954 | 6.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 37 | 37 | $49,101 | $7,975 | 16.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 31 | 65 | $29,055 | $7,174 | 24.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 73 | 73 | $17,650 | $5,072 | 28.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 25 | 25 | $25,379 | $4,997 | 19.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 40 | 40 | $11,640 | $4,469 | 38.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 40 | 68 | $10,540 | $4,131 | 39.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $10,435 | $3,707 | 35.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 25 | 25 | $32,465 | $3,532 | 10.9% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 21 | 21 | $19,728 | $3,070 | 15.6% |
| 43450 | Dilation of esophagus | Facility | 2022 | 29 | 30 | $16,650 | $1,001 | 6.0% |
About Dr. Jay Malamut, M.D
Dr. Jay Malamut, M.D is a Specialist healthcare provider based in Haddon Heights, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1881682367.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jay Malamut, M.D has received a total of $6,548 in payments from pharmaceutical and medical device companies, with $276.96 received in 2023. These payments were reported across 439 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($6,068).
As a Medicare-enrolled provider, Malamut has provided services to 3,317 Medicare beneficiaries, totaling 34,456 services with total Medicare billing of $899,508. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Practice Information
- Specialty Specialist
- Other Specialties Gastroenterology
- Location Haddon Heights, NJ
- Active Since 10/10/2005
- Last Updated 05/31/2023
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1881682367
Products in Payments
- XIFAXAN (Drug) $831.67
- STELARA (Biological) $683.14
- Humira (Biological) $405.35
- PillCam (Device) $322.96
- LINZESS (Drug) $252.60
- Mavyret (Drug) $197.83
- Cimzia (Drug) $177.27
- Entyvio (Biological) $171.80
- INJECTAFER (Drug) $170.31
- Creon (Drug) $169.02
- REMICADE (Biological) $167.22
- ENTYVIO (Biological) $142.83
- CLENPIQ (Drug) $138.11
- VIBERZI (Drug) $118.94
- XIFIXAN (Drug) $118.72
- HUMIRA (Biological) $117.63
- Sucraid (Drug) $117.50
- APRISO (Drug) $115.02
- MAVYRET (Drug) $112.31
- RINVOQ (Biological) $111.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Haddon Heights
John Kolnik, D.o, D.O
Specialist — Payments: $158,544
James Izanec, Md, MD
Specialist — Payments: $14,506
M Arif Hashmi, M.d, M.D
Specialist — Payments: $6,424
Dr. Denise Mastromonaco, D.o, D.O
Specialist — Payments: $2,690
Boris Libster, D.o, D.O
Specialist — Payments: $1,410
Howard Siegel, M.d, M.D
Specialist — Payments: $1,353